Linda Goler Blount, MPH, to Join ICER Governance Board
Linda Goler Blount, MPH, has been elected to join the governance board of the Institute for Clinical and Economic Review. Blount has worked in health policy and is currently the president of the Black Women’s Health Imperative. She has built a career on addressing health disparities, especially those disproportionately affecting Black women and girls.
ICER Report Suggests Lower Price for Lecanemab Than Aduhelm
The Institute for Clinical and Economic Review (ICER) has issued a report evaluating the value and cost-effectiveness of two amyloid-targeted therapeutics for Alzheimer's disease. Biogen and Eisai’s lecanemab was deemed by the agency to be cost effective if priced between $9,000 and $21,000, whereas Eli Lilly’s donanemab was valued between $14,500 and $46,900, although evidence was limited regarding the latter.
BioMarin’s Gene Therapy Roctavian More Cost-Effective in Hemophilia A than Genentech and Chugai’s Hemlibra
ICER has released a draft report that indicates Roctavian, BioMarin’s new gene therapy for hemophilia A, will beat the current antibody-based therapeutic Hemlibri. Unlike Hemlibri, which is a prophylactic, Roctavian restores the gene lacking in hemophilia A, factor VIII. The organization predicts that the one-time price of $2.5 million for Roctavian will be substantially lower than that of 12 years worth of Hemlibra at $640,000 annually.
ICER Review Casts Doubt on Value of Two ALS Drug Candidates
A new report by the Institute for Clinical and Economic Review (ICER) finds that 2 amytrophic lateral sclerosis (ALS) drug candidates from Amylyx and Mitsubishi Tanabe Pharma America have “low long-term value at their current suggested prices. Although the drugs both provide some benefits over the standard of care, the benefits do not justify the high price tag, the report notes.
ICER Report At a Glance: Beti-Cel for Beta Thalassemia
Beta Thalassemia is a blood disorder that results in dangerously low levels of functional hemoglobin and requires expensive lifelong medical care, including regular blood transfusions. Beti-cel is a gene therapy by Bluebird Bio that can potentially cure the disorder by genetically modifying a patient's own hematopoietic stem cells (HSCs). The Institute for Clinical and Economic Review (ICER) has just released its assessment of Beti-cel, finding that it is effective and could save money on treatment, but more comprehensive long-term data would be necessary to determine the degree of the net health benefit over the current standard of care.
ICER Announces Initiative to Develop Health Equity-Targeted HTA Practices
Health technology assessment (HTA) agencies are primarily focused on efficacy and safety of a therapeutic on a general population. A [...]
ICER Signals Concern About Price for Amylyx’s ALS Drug
The Institute for Clinical and Economic Review (ICER) has released a draft report detailing their concerns surrounding Amylyx Pharmaceutical’s new [...]
ICER Will Assess Value and Effectiveness of Multiple Sclerosis Treatments
The Institute for Clinical and Economic Review (ICER) will perform value and effectiveness assessments on several drugs for multiple sclerosis. [...]
ICER White Paper – Rare Disease Drug Policy Reform, Drug Access, and Innovation
Despite the advancements in rare disease treatment, patients with many rare diseases still have extremely limited, if any, treatment options. [...]
ICER Will Develop California State Unsupported Price Reports
The California Health Care Foundation (CHCF) has awarded The Institute for Clinical and Economic Review (ICER) a new grant to [...]
ICER: Final Evidence Report and Policy Recommendations on Tirzepatide Now Available
The Institute for Clinical and Economic Review (ICER) just released their final evidence report on the diabetes 2 drug terzepatide. [...]
ICER Releases Draft Report on Plinabulin and Trilaciclib for Chemo-induced Neutropenia
The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for the novel drugs plinabulin (BeyondSpring [...]
ICER Releases Evidence Report for Type 2 Diabetes Drug Tirzepatide
The Institute for Clinical and Economic Review (ICER) has released their revised evidence report for Eli Lilly’s new type 2 [...]
Final ICER Evidence Report on Tezepelumab for Severe Asthma
A final evidence report for the clinical effectiveness and value of Tezepelumab, a treatment for severe asthma, has been released [...]
Gene Therapy for Beta Thalassemia Gene Under ICER Assessment
A gene therapy for beta thalassemia will undergo ICER assessment for comparative clinical effectiveness and value. Betibeglogene autotemcel (Zynteglo/LentiGlobin) from [...]
Upcoming ICER Webinar Will Discuss Barriers to Fair Access
On December 3rd (12 PM), the Institute for Clinical and Economic Review will host a public webinar detailing the findings [...]
Panalgo and HealthEconomics.Com Host Webinar on Successful ICER Strategies
Panalgo and HealthEconomics.Com hosted a webinar detailing strategies that lead to successful evaluation by the Institute for Clinical and Economic [...]
Xcenda HEOR Experts Discuss ICER’s UPI Assessments
Xcenda’s Tasmina Hydery and Anne Loos shared their thoughts on the methodologies used by the Institute for Clinical and Economic [...]
ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and [...]
ICER Publishes Annual Hit List of 10 Drugs With Unsupported Price Hikes
The Institute for Clinical and Economic Review (ICER) has released its most recent report on Unsupported Price Increases (UPIs) for 2020. [...]
ICER Releases Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy Ahead of FDA Approval
The Institute for Clinical and Economic Review (ICER) has released its evidence report for mavacamten, used to treat hypertrophic cardiomyopathy [...]
Panalgo VP Discusses Changes to ICER’s Value Assessments Ahead of Mid-November Webinar
HealthEconomics.Com Founder and CEO Dr. Patti Peeples recently spoke with Panalgo’s Matt Sussman regarding changes to the value assessments carried [...]
Preparing a Successful ICER Strategy: Lessons from the Frontlines
Consequential prescription drug pricing decisions in the United States increasingly involve high-stakes interactions between the manufacturer and the Institute for Clinical and Economic Review (ICER).
ICER’s Final Evidence Report for Two Myasthenia Gravis Therapies Now Available
The Institute for Clinical and Economic Review (ICER) has published its final evidence report for two drugs used to treat [...]
ICER VP of Research Recognized as Emerging Health Leader, Seeks to Improve Health Equity
Foluso Agboola, a Nigerian researcher who pursued her training at Harvard before joining the Institute for Clinical and Economic Review [...]
